Share this article on:

Characteristics and Outcomes OF Acute Otitis Media in Children Carrying Streptococcus Pneumoniae or Haemophilus Influenzae in Their Nasopharynx as a Single Otopathogen After Introduction of the Heptavalent Pneumococcal Conjugate Vaccine

Caeymaex, Laurence PhD*†; Varon, Emmanuelle MD; Levy, Corinne MD; Béchet, Stéphane§; Derkx, Véronique MD§; Desvignes, Véronique MD; Doit, Catherine MD; Cohen, Robert MD*†§

The Pediatric Infectious Disease Journal: May 2014 - Volume 33 - Issue 5 - p 533–536
doi: 10.1097/INF.0000000000000213
Brief Reports

After PCV7 implementation, clinical characteristics were investigated in 832 young children with acute otitis media, carrying a single S. pneumoniae or H. influenzae in their nasopharynx. As compared with H. influenzae, S. pneumoniae-associated acute otitis media was less frequently associated with treatment failure (odds ratio = 0.5; 95% confidence interval: 0.36–0.83) and recurrence (odds ratio = 0.4; 95% confidence interval: 0.22–0.75). Post-PCV7 serotype replacement seemed not to affect the acute otitis media characteristics in these children.

From the *Clinical Research Centre (CRC), Centre Hospitalier Intercommunal Créteil, France; Service de Médecine néonatale, Centre Hospitalier Intercommunal Créteil, France; National Reference Center for Pneumococci, AP-HP, Hôpital Européen Georges Pompidou, Université Paris 5, Paris; §Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint Maur des Fossés; Association Française de Pédiatrie Ambulatoire, Gradignan; and Service de Microbiologie, Hôpital Robert-Debré (AP-HP), Université Paris-Diderot, Paris, France.

Accepted for publication October 15, 2013.

Corinne Levy, member of ACTIV, received honorarium and payment for lectures from Pfizer and Novartis. ACTIV received payment by Pfizer to conduct the study. ACTIV received grants for travel to meetings for the study and other purposes. Robert Cohen, member of ACTIV, received consulting fees, honorarium and payment for lectures from Pfizer, GSK, Novartis and SAF. This work was supported by Pfizer France. The funder had a role in the collection of data, as the research institution (ACTIV) received payment by Pfizer to conduct the study. The funder had no role in the study design and analysis. The authors have no other funding or conflicts of interest to disclose.

Address for correspondence: Laurence Caeymaex, Clinical Research Center, CRC Centre Hospitalier Intercommunal Créteil, 40 avenue de Verdun, 94010 Créteil. E-mail:

© 2014 by Lippincott Williams & Wilkins, Inc.